BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26174908)

  • 1. Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2015 Oct; 94(10):1655-65. PubMed ID: 26174908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
    Weiss L; Melchardt T; Habringer S; Boekstegers A; Hufnagl C; Neureiter D; Hopfinger G; Greil R; Egle A
    Ann Oncol; 2014 Jan; 25(1):171-6. PubMed ID: 24299961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.
    Bendtsen MD; Munksgaard PS; Severinsen MT; Bekric E; Brieghel C; Nielsen KB; Brown PN; Dybkaer K; Johnsen HE; Bøgsted M; El-Galaly TC
    Eur J Haematol; 2017 Apr; 98(4):355-362. PubMed ID: 27893172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Hematol Oncol; 2018 Feb; 36(1):76-83. PubMed ID: 28449294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis.
    Wang Z; Luo S; Zhao X
    Nutr Cancer; 2021; 73(11-12):2336-2346. PubMed ID: 32964748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
    Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
    Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.
    Carson KR; Bartlett NL; McDonald JR; Luo S; Zeringue A; Liu J; Fu Q; Chang SH; Colditz GA
    J Clin Oncol; 2012 Sep; 30(26):3217-22. PubMed ID: 22649138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
    Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
    Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
    Beltran BE; Paredes S; Castro D; Cotrina E; Sotomayor EM; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e551-e557. PubMed ID: 31320254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.
    Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Shi Y
    Leuk Res; 2021 Nov; 110():106715. PubMed ID: 34598076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.
    He J; Yin H; Xia Y; Wu JZ; Liang JH; Zhu HY; Fan L; Li JY; Wang L; Xu W
    Leuk Res; 2021 Nov; 110():106664. PubMed ID: 34271293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
    Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
    BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
    Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
    [No Abstract]   [Full Text] [Related]  

  • 18. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
    Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.